S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
MarketBeat Week in Review – 1/30 - 2/3
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
State of the Union: Biden sees economic glow, GOP sees gloom
Why a new Alzheimer's drug is having a slow US debut
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Sri Lanka marks independence anniversary amid economic woes
Tesla hikes price of Model Y after US alters tax credit rule
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Disney World unions vote down offer covering 45,000 workers
Route to Super Bowl dangerous for Mexico's avocado haulers
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
MarketBeat Week in Review – 1/30 - 2/3
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
State of the Union: Biden sees economic glow, GOP sees gloom
Why a new Alzheimer's drug is having a slow US debut
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Sri Lanka marks independence anniversary amid economic woes
Tesla hikes price of Model Y after US alters tax credit rule
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Disney World unions vote down offer covering 45,000 workers
Route to Super Bowl dangerous for Mexico's avocado haulers
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
MarketBeat Week in Review – 1/30 - 2/3
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
State of the Union: Biden sees economic glow, GOP sees gloom
Why a new Alzheimer's drug is having a slow US debut
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Sri Lanka marks independence anniversary amid economic woes
Tesla hikes price of Model Y after US alters tax credit rule
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Disney World unions vote down offer covering 45,000 workers
Route to Super Bowl dangerous for Mexico's avocado haulers
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
MarketBeat Week in Review – 1/30 - 2/3
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
State of the Union: Biden sees economic glow, GOP sees gloom
Why a new Alzheimer's drug is having a slow US debut
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Sri Lanka marks independence anniversary amid economic woes
Tesla hikes price of Model Y after US alters tax credit rule
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Disney World unions vote down offer covering 45,000 workers
Route to Super Bowl dangerous for Mexico's avocado haulers
NASDAQ:GOSS

Gossamer Bio - GOSS Stock Forecast, Price & News

$2.78
-0.14 (-4.79%)
(As of 02/3/2023 12:00 AM ET)
Add
Compare
Today's Range
$2.76
$2.98
50-Day Range
$1.74
$9.29
52-Week Range
$1.57
$15.19
Volume
4.03 million shs
Average Volume
3.53 million shs
Market Capitalization
$262.65 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.25

Gossamer Bio MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.60 Rating Score
Upside/​Downside
268.7% Upside
$10.25 Price Target
Short Interest
Bearish
38.34% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.67
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.75) to ($2.42) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.16 out of 5 stars

Medical Sector

393rd out of 1,028 stocks

Pharmaceutical Preparations Industry

188th out of 501 stocks

GOSS stock logo

About Gossamer Bio (NASDAQ:GOSS) Stock

Gossamer Bio, Inc. engages in discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. Its primary product candidate, GB001, is intended for the treatment of moderate-to-severe eosinophilic asthma and other allergic conditions. The company was founded by Faheem Hasnain and Sheila Gujrathi on October 25, 2015 and is headquartered in San Diego, CA.

Receive GOSS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Gossamer Bio and its competitors with MarketBeat's FREE daily newsletter.

GOSS Stock News Headlines

A gold storm is coming…
“We are in the early stages of a mania – the calm before the storm.”...
A gold storm is coming…
“We are in the early stages of a mania – the calm before the storm.”...
What 9 Analyst Ratings Have To Say About Gossamer Bio
Gossamer Bio selloff is an overreaction - Piper Sandler
4 Analysts Have This to Say About Gossamer Bio
Gossamer Bio
What 5 Analyst Ratings Have To Say About Gossamer Bio
Gossamer Bio, Inc. (GOSS)
See More Headlines
Receive GOSS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Gossamer Bio and its competitors with MarketBeat's FREE daily newsletter.

GOSS Company Calendar

Last Earnings
11/08/2021
Today
2/05/2023
Next Earnings (Estimated)
3/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:GOSS
Fax
N/A
Employees
185
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$10.25
High Stock Price Forecast
$24.00
Low Stock Price Forecast
$2.00
Forecasted Upside/Downside
+268.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.60
Research Coverage
10 Analysts

Profitability

Net Income
$-234,000,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.59 per share

Miscellaneous

Free Float
86,635,000
Market Cap
$262.65 million
Optionable
Not Optionable
Beta
1.18

Key Executives

  • Faheem Hasnain
    Chairman, President & Chief Executive Officer
  • Bryan GiraudoBryan Giraudo
    Chief Operating & Financial Officer
  • Richard Aranda
    Chief Medical Officer
  • Laura CarterLaura Carter
    Chief Scientific Officer
  • Christian Waage
    Secretary, General Counsel & Executive VP













GOSS Stock - Frequently Asked Questions

Should I buy or sell Gossamer Bio stock right now?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gossamer Bio in the last twelve months. There are currently 1 sell rating, 2 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" GOSS shares.
View GOSS analyst ratings
or view top-rated stocks.

What is Gossamer Bio's stock price forecast for 2023?

10 brokerages have issued 1 year price targets for Gossamer Bio's stock. Their GOSS share price forecasts range from $2.00 to $24.00. On average, they predict the company's share price to reach $10.25 in the next twelve months. This suggests a possible upside of 268.7% from the stock's current price.
View analysts price targets for GOSS
or view top-rated stocks among Wall Street analysts.

How have GOSS shares performed in 2023?

Gossamer Bio's stock was trading at $2.17 on January 1st, 2023. Since then, GOSS shares have increased by 28.1% and is now trading at $2.78.
View the best growth stocks for 2023 here
.

When is Gossamer Bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 2nd 2023.
View our GOSS earnings forecast
.

How were Gossamer Bio's earnings last quarter?

Gossamer Bio, Inc. (NASDAQ:GOSS) posted its earnings results on Monday, November, 8th. The company reported ($0.80) earnings per share for the quarter, missing analysts' consensus estimates of ($0.78) by $0.02. During the same quarter in the previous year, the company earned ($0.80) EPS.

What other stocks do shareholders of Gossamer Bio own?
When did Gossamer Bio IPO?

(GOSS) raised $230 million in an IPO on Friday, February 8th 2019. The company issued 14,400,000 shares at a price of $16.00 per share. BofA Merrill Lynch, Leerink Partners, Barclays and Evercore ISI acted as the underwriters for the IPO.

What is Gossamer Bio's stock symbol?

Gossamer Bio trades on the NASDAQ under the ticker symbol "GOSS."

Who are Gossamer Bio's major shareholders?

Gossamer Bio's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Birchview Capital LP (0.10%), Simplex Trading LLC (0.00%), New York State Common Retirement Fund (0.05%), Sequoia Financial Advisors LLC (0.03%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Bryan Giraudo, Caryn Peterson, Faheem Hasnain, Laura Carter, Luisa Salter-Cid, Richard Aranda and Waage Christian.
View institutional ownership trends
.

How do I buy shares of Gossamer Bio?

Shares of GOSS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Gossamer Bio's stock price today?

One share of GOSS stock can currently be purchased for approximately $2.78.

How much money does Gossamer Bio make?

Gossamer Bio (NASDAQ:GOSS) has a market capitalization of $262.65 million. The company earns $-234,000,000.00 in net income (profit) each year or ($2.89) on an earnings per share basis.

How many employees does Gossamer Bio have?

The company employs 185 workers across the globe.

How can I contact Gossamer Bio?

Gossamer Bio's mailing address is 3013 SCIENCE PARK, SAN DIEGO CA, 92121. The official website for the company is www.gossamerbio.com. The company can be reached via phone at (858) 684-1300 or via email at ir@gossamerbio.com.

This page (NASDAQ:GOSS) was last updated on 2/5/2023 by MarketBeat.com Staff